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Abstract
Background: A low body mass index (BMI) at antiretroviral therapy (ART) initiation is a strong predictor of
mortality among HIV-infected adults in resource-constrained settings. The relationship between nutrition and
inflammation-related serum biomarkers and early treatment outcomes (e.g., less than 90 days) in this population is
not well described.
Methods: An observational cohort of 142 HIV-infected adults in Lusaka, Zambia, with BMI under 16 kg/m
2 or CD4
+
lymphocyte counts of less than 50 cells/mm
3, or both, was followed prospectively during the first 12 weeks of ART.
Baseline and serial post-treatment phosphate, albumin, ferritin and highly sensitive C-reactive protein (hsCRP)
serum levels were measured. The primary outcome was mortality.
Results: Lower baseline phosphate and albumin serum levels, and higher ferritin and hsCRP, were significantly
associated with mortality prior to 12 weeks (p < 0.05 for all comparisons), independent of known risk factors for
early ART-associated mortality in sub-Saharan Africa. The time-dependent interval change in albumin was
associated with mortality after adjusting for the baseline value (AHR 0.62 [0.43, 0.89] per 5 g/L increase), but
changes in the other biomarkers were not.
Conclusions: The predictive value of serum biomarkers for early mortality in a cohort of adults with malnutrition
and advanced HIV in a resource-constrained setting was primarily driven by pre-treatment values, rather than post-
ART changes. Interventions to promote earlier HIV diagnosis and treatment, address nutritional deficiencies, and
identify the etiologies of increased systemic inflammation may improve ART outcomes in this vulnerable
population.
Background
The combination of untreated HIV infection and a poor
nutritional state interact in a complex cycle that hastens
both immunosuppression and weight loss, and a low
body mass index (BMI) (less than 18.5 kg/m
2)i sa
powerful predictor of early mortality following antiretro-
viral therapy (ART) initiation in several reports from
resource-constrained settings [1-4]. A reduced serum
albumin level, potentially due to inflammatory cytokine-
induced inhibition of protein synthesis, inadequate
nutritional intake, or other causes, is also associated
with increased mortality in HIV-infected adults [5-8].
Similarly, heightened systemic inflammation, including
elevated serum levels of C-reactive protein (CRP) and
ferritin (an acute phase reactant), is associated with
accelerated loss of lean body mass and a more rapid
progression to AIDS and death [9-12].
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levels at ART initiation are independently and negatively
associated with early mortality in an observational
cohort of severely malnourished (BMI below 16 kg/m
2)
and/or immunosuppressed (CD4
+ lymphocyte count
below 50 cells/mm
3) adults initiating treatment in
Lusaka, Zambia [13]. A central hypothesis was that a
variant of the refeeding syndrome, or an early, precipi-
tous drop in serum phosphate in response to increased
metabolic activity and/or carbohydrate intake among
malnourished individuals starting ART contributed to
the high rates of early mortality among low BMI adults
in sub-Saharan Africa [14,15]. However, we found no
association between one-week post-ART phosphate
levels and subsequent mortality, suggesting that acute
electrolyte derangements were not a proximate cause of
death in most instances.
Prior studies have demonstrated associations between
long-term (i.e., more than six months) changes in
inflammatory biomarkers or albumin, and subsequent
health outcomes in persons living with HIV [16,17], but
the relationship between these biomarkers and mortality
in the immediate post-ART period is not well studied,
especially in resource-constrained settings. In this analy-
sis, we describe relationships between pre-treatment
levels and post-ART changes in serum phosphate, albu-
min, ferritin and CRP and the risk of mortality in the
first 12 weeks of ART in a cohort of adults in sub-
Saharan Africa with advanced malnutrition and
immunosuppression.
Methods
We enrolled 142 HIV-infected adults with a BMI of less
than 16 kg/m
2 or a CD4
+ lymphocyte count below 50
cells/mm
3 initiating ART at a public sector clinic in
Lusaka, Zambia, in an observational, prospective cohort
study to assess metabolic predictors of all-cause mortality
in the first 12 weeks of treatment. The study setting, elig-
ibility criteria, design and procedures have been pre-
viously described [13]. Briefly, individuals were eligible
for enrolment if they: qualified for ART according to
Zambian national guidelines in place at the time (i.e.,
WHO stage 4 disease, a CD4
+ lymphocyte count below
200 cells/mm
3, or WHO stage 3 disease and a CD4
+ lym-
phocyte count below 350 cells/mm
3); were intending to
start therapy the same day; met the BMI and/or CD4
+
threshold criteria; and agreed to adhere to the study visit
schedule and laboratory testing requirements.
At the enrolment visit and the subsequent study visits
at one, two, four, eight and 12 weeks post-ART initia-
tion, participants were evaluated by a research nurse
and a clinical officer and/or a supervising physician.
The first-line ART regimen was selected from the
national programme formulary: two nucleoside reverse
transcriptase inhibitors in combination with one non-
nucleoside reverse transcriptase inhibitor.
At the initial visit, a detailed health history, review of
systems, physical examination and laboratory testing
(including a basic metabolic panel, serum phosphate,
albumin, ferritin and highly-sensitive C-reactive protein)
were performed. Phosphate and albumin were measured
at each subsequent study visit, while ferritin measure-
ments were repeated at one, two, four and 12 weeks,
and highly sensitive C-reactive protein (hsCRP) mea-
surements were repeated at one, four and 12 weeks
post-ART initiation. Thirteen participants received
phosphate supplementation according to predetermined
algorithm based on serum level [13].
Participant deaths were reported to the study staff by
the health clinic. If a participant missed a study visit
and could not be contacted by phone, community out-
reach teams attempted to locate the individual or a
close relative to determine the vital status [18]. If the
participant could not be located and vital status was
unknown, he or she was deemed lost to follow up.
Routine and study-specific chemistry assays were mea-
sured using a Roche COBAS Integra 400+ (Roche Diag-
nostics, Basel, Switzerland) or a Pointe 180 Chemistry
Analyzer (Pointe Scientific, Canton, MI, USA). CD4
+
lymphocyte counts were performed using a Beckman
Coulter Epics XL-MCL flow cytometer (Beckman Coul-
t e r ,I n c . ,F u l l e r t o n ,C A ,U S A ) ,a n dh e m o g r a mu s i n ga
Horiba ABX Pentra 80 (Horiba ABX Diagnostics Inc.,
Montpellier, France).
Cox proportional hazards models were used to assess
the relationship between the baseline nutrition or
inflammation serum biomarker values and time to
death. The biomarkers were modelled as continuous
variables and expanded using restricted cubic splines
to avoid linearity assumptions. To reduce the number
of variables in the Cox models, we used a principal
component analysis with age, hemoglobin, CD4
+ lym-
phocyte count and BMI to extract the first principal
factor to represent these variables at baseline. All Cox
models were adjusted for sex and this principal
component.
If the vital status at 90 days was unknown (i.e., lost to
follow up), the participant was censored at the last study
visit date. A second multivariable regression used similar
techniques to model the relationship between the base-
line biomarkers and a composite endpoint of time to
death or loss to follow up. We accounted for missing
baseline status values (29 hemoglobin, two ages, and
one BMI value) and serum biomarkers (eight phosphate,
22 albumin, and 58 hsCRP and ferritin values) using
multiple imputation techniques [19]. The proportion of
imputed values was within the commonly accepted
range [19].
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Page 2 of 8To visualize longitudinal data, we plotted the serum
indicators of interest for the alive, deceased and
deceased/lost cohorts against the number of days on
ART; each participant required a minimum of two
recorded values for inclusion (participants who had only
one recorded value, generally because they had died,
were excluded). For each variable, we sketched a locally
weighted scatterplot smoothing (LOWESS) curve by fit-
ting a polynomial surface using local (weighted) least
squares regression [20].
Cox models with baseline and time-dependent covari-
ates were used to assess the relationship between serial
biomarker values and time to death, or the composite
endpoint of time to death or loss to follow up. Each bio-
marker was modelled separately, and the model was
adjusted for the biomarker baseline serum value, in
addition to sex and the principal component (as already
described). If the participant had no recorded serum
level within a given time interval (i.e., week one visit,
week four visit, etc.), he or she was dropped from the
risk set for that interval. R-software 2.11.0 (http://www.
r-project.org) was used for data analyses.
The study protocol and informed consent documents
were approved by the University of Zambia Research
Ethics Committee (Lusaka, Zambia), and the
Institutional Review Boards at the University of Alabama
at Birmingham (Birmingham, Alabama, USA) and Van-
derbilt University (Nashville, Tennessee, USA).
Results
We enrolled 142 participants between 6 November 2006
and 12 November 2007; 59 (42%) participants had BMI
below 16.0 kg/m
2 and 110 (77%) had CD4
+ lymphocyte
counts below 50 cells/mm
3 (27, or 19%, met both elig-
ibility criteria). Twenty-five participants died over the
12-week follow-up period (mortality rate: 87.4 per 100
person-years of follow up); 10 (40%) participants died
within four weeks of starting ART, although none died
in the first week. The median time to death was 34 days
(interquartile range [IQR]: 20, 54). Thirty-three partici-
p a n t s( 2 3 % )w e r el o s tt of o l l o wu p ;t h em e d i a nf o l l o w -
up time for those lost was 58 days (IQR: 45, 71). Table
1 describes participant characteristics, baseline serum
biomarker levels, and the distribution of first-line ART
regimens.
Table 2 describes the hazard of mortality or loss to
follow up across an observed range of baseline phos-
phate, albumin, ferritin and hsCRP serum values. A
serum phosphate of 1.0 mmol/L was associated with an
approximate 20% reduction in the hazard of mortality
Table 1 Baseline participant characteristics and serum biomarker values
Participant demographics and clinical characteristics
N 142
Female, n (%) 87 (61%)
Age, median years (IQR) 32 (28, 38)
Weight, median kg (IQR) 46 (41, 51)
BMI, median kg/m
2 (IQR) 16 (15, 19)
CD4
+ count, median cells/mm
3L (IQR) 34 (21, 47)
Hemoglobin, median g/dL (IQR) 9.8 (8.8, 11.6)
Baseline serum biomarker levels
Phosphate, median mmol/L (IQR) 1.26 (1.03, 1.42) [range 0.4-2.3]
Albumin, median g/L (IQR) 29.5 (23.9, 33.2) [range 13.1-49.5]
Ferritin, median μg/L (IQR) 221 (59, 485) [range 4-1332]
hsCRP, median mg/L (IQR) 2.8 (1.1, 15.2) [range 0.2-58.3]
ART regimen, n (%)
ZDV/3TC/EFV 8 (6%)
ZDV/3TC/NVP 34 (24%)
d4T/3TC/EFV 15 (11%)
d4T/3TC/NVP 62 (44%)
TDF/FTC/EFV 4 (3%)
TDF/FTC/NVP 19 (13%)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; hsCRP, highly sensitive C-reactive protein; IQR, interquartile range; 3TC, lamivudine; d4T,
stavudine; EFV, efavirenz; FTC, emtricitabine; NVP, nevirapine; TDF; tenofovir; ZDV, zidovudine.
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interval: 0.67, 0.93]) compared with a value of 0.87
mmol/L (i.e., the low end of the normal range) [21]. A
serum albumin of 30 g/L compared with 25 g/L was
associated with a nearly 50% reduced hazard of mortal-
ity (AHR 0.52 [0.38, 0.70]).
Conversely, higher baseline serum ferritin and hsCRP
levels were associated with increased mortality; com-
pared with a ferritin value of 25 μg/L, a baseline serum
level of 250 μg/L was associated with an approximate
67% increased hazard of mortality at 12 weeks (AHR
1.67 [1.30, 2.15]), and a value of 1000 μg/L was asso-
ciated with a nearly 10-fold increased hazard (AHR 9.28
[3.13, 27.50]). A baseline hsCRP level of 15 mg/L was
associated with a nearly two-fold increased hazard of
d e a t hc o m p a r e dw i t hav a l u eo f5m g / L( A H R1 . 9 6
[1.12, 3.44]).
All adjusted hazard ratios were significantly different
from zero (p < 0.05). The calculated hazard of reaching
the combined endpoint of mortality or loss to follow up
for each gradation of the serum indicators was less pro-
nounced compared with the hazard of mortality alone,
and the association was not statistically significant for
phosphate or hsCRP.
Figure 1 shows serial phosphate, albumin, ferritin and
hsCRP values for each participant alive, deceased or lost
to follow up at 12 weeks (grey lines) and the LOWESS
curve (black line). Serum phosphate appeared to be rela-
tively stable from ART initiation to 12 weeks among
retained survivors, while albumin gradually rose and
both ferritin and hsCRP declined. Similar plots among
the deceased were truncated, but were notable for lower
baseline phosphate and albumin, and higher ferritin and
hsCRP levels with steeper initial declines. The baseline
values among participants lost to follow up approxi-
mated the survivors, but the LOWESS curves showed a
drop in phosphate post-ART and no apparent early
increase in albumin.
Table 3 describes the association between time-
updated serum biomarkers and the attendant hazard of
mortality, or the combined endpoint of mortality or loss
to follow up, prior to 12 weeks. The Cox model for
each biomarker was adjusted for the baseline serum bio-
marker value, to account for the associations between
baseline values and outcome demonstrated in Table 2.
The reported adjusted hazard ratios represent the esti-
mated ratio of the hazard of death, at any time prior to
12 weeks, for a hypothetical pair of participants whose
Table 2 Adjusted hazard ratios for mortality and loss to follow up at 90 days
Baseline serum biomarker AHR mortality (95% CI)
a p-value AHR mortality or loss to follow up (95% CI) p-value
Phosphate, mmol/L
0.87 (ref) 1.00 0.016 1.00 0.855
1.0 0.79 (0.67, 0.93) 0.97 (0.88, 1.08)
1.5 0.31 (0.14, 0.69) 0.87 (0.53, 1.43)
Albumin, g/L
25 (ref) 1.00 <0.001 1.00 <0.001
30 0.52 (0.38, 0.70) 0.65 (0.53, 0.79)
35 0.49 (0.24, 1.01) 0.72 (0.48, 1.08)
Ferritin, μg/L
25 (ref) 1.00 <0.001 1.00 0.002
250 1.67 (1.30, 2.15) 1.37 (1.15, 1.62)
1000 9.28 (3.13, 27.50) 3.86 (1.83, 8.17)
hsCRP, mg/L
5 (ref) 1.00 0.027 1.00 0.103
10 1.56 (1.04, 2.33) 1.27 (1.00, 1.62)
15 1.96 (1.12, 3.44) 1.41 (1.01, 1.95)
a Models adjusted for sex and a first principal component (incorporating age, body mass index, CD4
+ lymphocyte count, and haemoglobin).
Abbreviation: hsCRP, highly sensitive C-reactive protein.
Note: There was evidence that the association between albumin and hsCRP, and the hazard of death was non-linear (p < 0.10), and there was evidence that the
association between albumin and the hazard of the combined endpoint of mortality and loss to follow up was non-linear (p < 0.10).
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(shown in parentheses in the left column).
For interval increases in phosphate, ferritin and
hsCRP, the adjusted hazard ratios demonstrated a trend
in the same direction as the hazard ratios for interval
changes in the baseline biomarker values (Table 2), but
the association was not statistically significant for either
death or the combined endpoint. However, a 5 g/L
increase in albumin was significantly associated with a
nearly 40% reduction in the hazard of death (AHR 0.62
Phosphate (mmol/L)
Alive Dead Dead or lost to follow up
Time post-ART (days)
Albumin (g/L)
Time post-ART (days)
Ferritin (g/L)
Time post-ART (days)
hsCRP (mg/L)
Time post-ART (days)
Figure 1 Biomarker levels among participants alive, deceased, and lost to follow up at 90 days post-ART initiation. Each grey line
represents a single participant; a black line represents the locally weighted scatterplot smoothing (LOWESS) curve.
Table 3 Time-dependent predictors of mortality and loss to follow up at 90 days, adjusted for baseline biomarker
value
Serum biomarker Adjusted HR
mortality
(95% CI)
a
p-value Adjusted HR mortality or
loss to follow up
(95% CI)
p-value
Phosphate (per 0.1 mmol/L increase) 0.90 (0.77, 1.05) 0.178 0.97 (0.87, 1.07) 0.529
Albumin (per 5 g/L increase) 0.62 (0.43, 0.89) 0.010 0.70 (0.56, 0.87) 0.002
Ferritin (per 100 μg/L increase) 1.05 (0.89, 1.24) 0.536 1.05 (0.93, 1.19) 0.428
hsCRP (per 5 mg/L increase) 1.25 (0.74, 2.12) 0.390 1.33 (0.87, 2.03) 0.184
a Models adjusted for the baseline value of each biomarker, sex, and a first principal component (incorporating age, body mass index, CD4+ lymphocyte count,
and hemoglobin).
Abbreviation: hsCRP, highly sensitivite C-reactive protein.
Note: Participants with no lab values were dropped from the Cox models, and time intervals with no corresponding serum level are excluded from analysis.
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Page 5 of 8[0.43, 0.89]), and an approximate 30% reduction in the
hazard of the combined endpoint (AHR 0.70 [0.56,
0.87]).
We previously reported that baseline serum phosphate
predicted early mortality in our cohort [13], so we
incorporated serum phosphate into the first principal
component of the adjusted Cox models of baseline albu-
min, ferritin and hsCRP to assess for confounding (data
not shown). The associations of baseline albumin, ferri-
tin and hsCRP with mortality (shown in Table 2)
remained statistically significant (p < 0.01, p < 0.01, and
p = 0.03, respectively).
We also repeated the time-dependent Cox analyses by
“carrying forward” the last recorded laboratory value for
each serum biomarker until the next recorded value or
until death, loss to follow up or study termination
occurred (rather than dropping intervals without a cor-
responding value from the analysis, as we have reported
here). An interval increase in albumin remained a signif-
icant predictor of mortality and the composite endpoint
(p = 0.008 and p = 0.001, respectively) while interval
changes in phosphate, ferritin and hsCRP remained
non-significant.
Conclusions
We found that pre-treatment nutrition and inflamma-
tion serum biomarker levels were associated with mor-
tality prior to 12 weeks among adults with advanced
malnutrition and/or immunosuppression initiating ART
in a resource-constrained setting. A post-treatment
interval change in albumin was also a significant predic-
tor of early mortality, while changes in phosphate, ferri-
tin and hsCRP were not. Our study is the first to
describe the relationship of these biomarkers to survival
in the immediate post-ART period among patients in
the advanced stages of HIV disease, but our findings
support similar prior studies investigating longer term
health outcomes [7,10-12,16,17,22].
These findings do not imply a causal relationship
between elevated inflammation biomarkers or low phos-
phate or albumin and health outcomes, as individuals
with untreated HIV and advanced malnutrition likely
have multiple complex metabolic and physiologic
derangements. Systemic inflammation in the setting of
HIV infection may be a response to occult opportunistic
infections, HIV-1 replication, immune reconstitution
inflammatory syndrome, or other conditions. Elevated
ferritin, in particular, may principally represent a reac-
tion to infectious agents. The pathophysiologic processes
contributing to mortality in the immediate post-ART
period are a critical research uncertainty and likely differ
from those present after several months or years on
treatment.
Prior studies have reported greater baseline immune
activation in cohorts of HIV-infected and non-infected
African adults compared with similar groups in the US
and Europe [23-25]. This “background” immune activa-
tion may represent opportunistic co-infections (e.g.,
tuberculosis) or common region-specific infections (e.g.,
helminthes or malaria parasites), or it could be related
to infection with HIV-1 subtype C compared with other
viral subtypes [26]. Elevated CRP and other inflamma-
tion biomarkers are associated with endothelial dysfunc-
tion and an increased risk of cardiovascular events
[27,28]; the effect of chronic immune activation on
inflammation-related processes (e.g., coronary athero-
sclerosis) in these populations is an area for further
research.
We previously reported that the absolute value of one-
week serum phosphate and the change from the pre-
treatment level were not significantly associated with
mortality in this cohort, as might be observed in the
refeeding syndrome [13]. This condition is classically
defined by electrolyte and fluid shifts over a period of
several weeks in response to increased carbohydrate
intake among nutritionally depleted individuals, which
predisposes to a range of cardiovascular, respiratory and
neurologic sequelae, and death [14,15,29]. The current
finding that interval increases in phosphate from treat-
ment initiation to 12 weeks were not associated with
reduced subsequent mortality may have been biased
toward the null hypothesis by protocol-specified phos-
phorus supplementation of participants with low levels
[13].
Relative long-term (i.e., longer than six month)
declines in serum albumin are associated with increased
mortality among HIV-infected women (both with and
without ART) [16], but absolute albumin values are an
uncertain indicator of nutritional status in the presence
of chronic inflammation. Albumin is a negative acute-
phase reactant, and albumin synthesis, degradation and
leakage from the vascular compartment are cytokine-
mediated processes [8,30]. Some data suggest systemic
inflammation is a stronger determinant of serum albu-
min levels than either protein intake or body protein
stores; however, a lower baseline serum albumin
remained significantly associated with mortality at 12
weeks after controlling for baseline hsCRP and ferritin
in our cohort (p < 0.01).
The time-dependent analyses of interval changes in
phosphate, ferritin and hsCRP demonstrated non-signifi-
cant hazard ratios that uniformly trended in the same
direction as the ratios for the baseline values, suggesting
that our study cohort was potentially not large enough
to detect a true association. Additionally, our analyses
adjusted for potential confounding variables, including
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+ lymphocyte count, BMI and hemoglobin,
but residual confounding and/or other unmeasured vari-
ables may have affected the associations between serum
biomarkers and mortality. Our study investigated rela-
tively few biomarkers of inflammation and nutrition;
future studies of early mortality should include a wider
range of variables (e.g., pre-albumin, interleukin-6, solu-
ble tumor necrosis factor receptors and ligands, mono-
cyte chemoattractant protein-1, urinary F-2 isoprostane,
and markers of T cell activation, among others).
Our cohort also had a high rate of participant attri-
tion, but the observed loss rates are similar to reports
from other programmatic cohorts in sub-Saharan Africa
[31]. It is likely that many of the lost participants repre-
sented unrecorded deaths or those who ceased treat-
ment and subsequently died. The presence or absence
of occult opportunistic infections could not be ade-
quately explored in this study because of limited diag-
nostic capabilities available in public-sector clinics in
Lusaka, Zambia. Finally, future studies would benefit
from careful ascertainment of a cause of death for each
participant, principally to determine the prevalence of
occult infections or inflammation-associated, non-AIDS-
defining events.
In this observational cohort study, pre-treatment
phosphate, albumin, ferritin and hsCRP serum levels
were associated with mortality in the first 12 weeks on
ART, but only the interval change in post-treatment
albumin was associated with this outcome, while
changes in the remaining biomarkers were not. The pre-
sence of increased baseline inflammation biomarkers
among those deceased at 12 weeks may indicate the pre-
sence of undiagnosed secondary infections, such as
tuberculosis, fungi and parasites.
Measurement of pre-treatment phosphate, albumin,
f e r r i t i na n dh s C R Ps e r u ml e v e l sm a yh a v ear o l ei nt h e
risk stratification of low BMI adults starting ART, and
in the future, could prompt additional diagnostic proce-
dures, trials of anti-inflammatory therapies, nutritional
supplementation, or other targeted intervention strate-
gies. The role of post-treatment monitoring of phos-
phate and inflammation biomarkers should be explored
in larger studies.
Low BMI individuals represent a considerable propor-
tion of adults requiring HIV care in resource-con-
strained settings, and further study of the metabolic and
physiologic derangements, co-morbid infections, and
potential therapeutic interventions to improve outcomes
in this vulnerable population are necessary.
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